,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,AC018755.18,,ENSG00000268500,,19,51612091-51646889,Predicted membrane proteins,Evidence at transcript level,HPA009085,Approved,,,,,Not detected,Tissue enhanced,,appendix: 10.0;bone marrow: 17.4,spleen: 5.5,Group enriched,14.0,HMC-1: 68.6;U-937: 25.7
1,ADAMTS8,"ADAM-TS8, FLJ41712, METH2",ENSG00000134917,ADAM metallopeptidase with thrombospondin type 1 motif 8,11,130404925-130428993,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at transcript level,HPA066349,Approved,,,,Endometrial cancer:1.38e-4 (favourable),Tissue enhanced,Tissue enhanced,,appendix: 10.9;lung: 15.5,seminal vesicle: 5.5,Cell line enhanced,,HMC-1: 3.2;NTERA-2: 1.8;U-2 OS: 8.7
2,ADCYAP1,PACAP,ENSG00000141433,Adenylate cyclase activating polypeptide 1,18,904943-912172,Predicted secreted proteins,Evidence at protein level,HPA065887,,Approved,,,Renal cancer:2.91e-6 (favourable),Tissue enhanced,Tissue enhanced,,appendix: 19.3;cerebral cortex: 16.0;gallbladder: 15.7,testis: 5.6,Cell line enriched,17.0,SCLC-21H: 20.8
3,ADGRE1,"EMR1, TM7LN3",ENSG00000174837,Adhesion G protein-coupled receptor E1,19,6887566-6940459,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at transcript level,HPA052809,Uncertain,,,,,Mixed,Tissue enhanced,,appendix: 9.9;spleen: 19.7,lung: 6.8,Cell line enhanced,,BJ hTERT+: 8.5;HDLM-2: 24.5;HMC-1: 15.9;Karpas-707: 16.0
4,ADGRE2,"CD312, EMR2",ENSG00000127507,Adhesion G protein-coupled receptor E2,19,14732393-14778541,"CD markers, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA055200,,,Uncertain,Vesicles,Renal cancer:4.35e-6 (unfavourable),Mixed,Tissue enhanced,,appendix: 27.0;spleen: 15.4,adipose tissue: 6.0,Cell line enhanced,,HEL: 10.6;HMC-1: 16.0;U-937: 11.8
5,ADGRE3,EMR3,ENSG00000131355,Adhesion G protein-coupled receptor E3,19,14619117-14690027,"G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA015638,Uncertain,,,,,Not detected,Tissue enhanced,,appendix: 8.7;spleen: 8.6,lung: 3.9,Cell line enriched,50.0,HMC-1: 39.7
6,APOBEC3A,"ARP3, PHRBN",ENSG00000128383,Apolipoprotein B mRNA editing enzyme catalytic subunit 3A,22,38952741-38992778,Predicted intracellular proteins,Evidence at protein level,"HPA043237, HPA056980, HPA066719",Approved,,Uncertain,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,appendix: 29.8;bone marrow: 59.0,spleen: 19.5,Not detected,,
7,AQP9,"HsT17287, SSC1",ENSG00000103569,Aquaporin 9,15,58138169-58185911,Predicted membrane proteins,Evidence at protein level,"HPA074762, CAB075684",Enhanced,,,,Renal cancer:5.72e-11 (unfavourable),Tissue enriched,Tissue enhanced,,appendix: 102.4;liver: 353.0,epididymis: 50.3,Cell line enriched,37.0,U-87 MG: 27.9
8,ARHGAP45,"HA-1, HMHA1, KIAA0223",ENSG00000180448,Rho GTPase activating protein 45,19,1065923-1086628,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA019816,Enhanced,,,,"Endometrial cancer:6.02e-4 (favourable), Head and neck cancer:7.82e-4 (favourable)",Expressed in all,Tissue enhanced,,appendix: 56.4;lymph node: 66.6;spleen: 77.8,bone marrow: 44.0,Cell line enhanced,,Karpas-707: 72.0;U-266/70: 99.7
9,BCL2A1,"ACC-1, ACC-2, ACC1, ACC2, BCL2L5, BFL1, GRS, HBPA1",ENSG00000140379,BCL2 related protein A1,15,79960889-79971446,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,Renal cancer:2.77e-5 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 115.2;bone marrow: 277.0,lymph node: 62.1,Cell line enhanced,,HMC-1: 76.7;SK-MEL-30: 329.3;U-138 MG: 43.6
10,C3AR1,"AZ3B, C3AR",ENSG00000171860,Complement C3a receptor 1,12,8058302-8066471,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,CAB009405,Enhanced,,,,,Expressed in all,Tissue enhanced,,appendix: 86.6,placenta: 49.5,Cell line enriched,9.0,HMC-1: 172.5
11,C5AR1,"C5A, C5AR, C5R1, CD88",ENSG00000197405,Complement C5a receptor 1,19,47290023-47322066,"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002720, HPA014520",Approved,,,,"Renal cancer:1.16e-4 (unfavourable), Cervical cancer:4.71e-4 (favourable), Testis cancer:7.99e-4 (unfavourable), Ovarian cancer:9.55e-4 (unfavourable)",Expressed in all,Tissue enhanced,,appendix: 121.2,adipose tissue: 91.2,Cell line enhanced,,HMC-1: 4.6;U-87 MG: 6.2;U-937: 5.1
12,CARMIL2,"LRRC16C, RLTPR",ENSG00000159753,Capping protein regulator and myosin 1 linker 2,16,67644919-67657569,Predicted intracellular proteins,Evidence at protein level,HPA041402,Approved,,,,,Mixed,Tissue enhanced,,appendix: 16.2;lymph node: 25.0;spleen: 15.1,tonsil: 10.1,Cell line enhanced,,Daudi: 45.8;MOLT-4: 51.3;REH: 96.9;RPMI-8226: 40.2;U-698: 73.2
13,CASS4,"C20orf32, HEFL, HEPL",ENSG00000087589,Cas scaffolding protein family member 4,20,56412112-56460387,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB034217,Approved,,,,,Mixed,Tissue enhanced,,appendix: 17.7;lung: 23.9,spleen: 10.7,Cell line enhanced,,HEL: 15.8;HMC-1: 45.4;K-562: 19.8
14,CCL11,"eotaxin, MGC22554, SCYA11",ENSG00000172156,C-C motif chemokine ligand 11,17,34285668-34288334,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,,,,,,"Head and neck cancer:1.99e-4 (favourable), Colorectal cancer:8.70e-4 (favourable)",Mixed,Tissue enhanced,,appendix: 39.3;small intestine: 37.3,duodenum: 30.8,Cell line enriched,18.0,BJ hTERT+: 7.2
15,CCL17,"ABCD-2, SCYA17, TARC",ENSG00000102970,C-C motif chemokine ligand 17,16,57404767-57416062,Predicted secreted proteins,Evidence at protein level,CAB002583,Approved,,,,"Cervical cancer:1.91e-5 (favourable), Urothelial cancer:5.80e-4 (favourable)",Mixed,Tissue enhanced,,appendix: 11.1;lymph node: 9.9,tonsil: 5.4,Cell line enriched,725.0,HDLM-2: 2231.6
16,CCL22,"A-152E5.1, ABCD-1, DC/B-CK, MDC, MGC34554, SCYA22, STCP-1",ENSG00000102962,C-C motif chemokine ligand 22,16,57358772-57366190,Predicted secreted proteins,Evidence at protein level,,,,,,"Endometrial cancer:2.23e-6 (favourable), Head and neck cancer:9.17e-5 (favourable), Colorectal cancer:2.98e-4 (favourable)",Mixed,Tissue enhanced,,appendix: 18.6;tonsil: 13.5,skin: 7.9,Cell line enriched,21.0,HDLM-2: 45.9
17,CCR1,"CD191, CKR-1, CMKBR1, MIP1aR, SCYAR1",ENSG00000163823,C-C motif chemokine receptor 1,3,46201709-46208396,"CD markers, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:1.01e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 57.5,spleen: 41.1,Cell line enhanced,,Karpas-707: 230.1;RPMI-8226: 105.8;U-266/84: 123.3
18,CCR2,"CC-CKR-2, CD192, CKR2, CMKBR2, FLJ78302, MCP-1-R",ENSG00000121807,C-C motif chemokine receptor 2,3,46353734-46360928,"CD markers, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,CAB003793,Approved,,,,Lung cancer:5.87e-4 (favourable),Mixed,Tissue enhanced,,appendix: 51.7,spleen: 20.5,Cell line enhanced,,Karpas-707: 195.5;THP-1: 89.5;U-266/70: 473.3;U-266/84: 185.8
19,CCR4,"CC-CKR-4, CD194, ChemR13, CKR4, CMKBR4, k5-5",ENSG00000183813,C-C motif chemokine receptor 4,3,32951574-32956349,"CD markers, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA031613,Approved,,,,,Mixed,Tissue enhanced,,appendix: 11.5,urinary bladder: 8.9,Cell line enriched,17.0,HDLM-2: 187.8
20,CD300E,"CD300LE, CLM2, IREM2",ENSG00000186407,CD300e molecule,17,74609887-74623738,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA015570,Uncertain,,,,,Mixed,Tissue enhanced,,appendix: 52.8;bone marrow: 29.0,adipose tissue: 18.0,Not detected,,
21,CD300LB,"CLM7, TREM5",ENSG00000178789,CD300 molecule like family member b,17,74521174-74531474,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,appendix: 11.4,spleen: 5.2,Cell line enhanced,,HL-60: 1.5;NB-4: 1.5;THP-1: 1.3
22,CD5,"LEU1, T1",ENSG00000110448,CD5 molecule,11,61102395-61127852,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB015392, CAB020308, HPA043416, HPA060839",Enhanced,,,,"Head and neck cancer:7.41e-6 (favourable), Renal cancer:8.94e-5 (unfavourable), Endometrial cancer:9.00e-5 (favourable), Cervical cancer:9.16e-5 (favourable), Melanoma:3.93e-4 (favourable), Breast cancer:4.05e-4 (favourable)",Mixed,Tissue enhanced,,appendix: 29.8;lymph node: 43.0,tonsil: 20.2,Cell line enriched,71.0,MOLT-4: 56.4
23,CD6,Tp120,ENSG00000013725,CD6 molecule,11,60971680-61020377,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002489, CAB016252",Enhanced,,,,"Head and neck cancer:5.10e-6 (favourable), Cervical cancer:1.57e-5 (favourable), Renal cancer:1.82e-4 (unfavourable), Breast cancer:1.95e-4 (favourable), Endometrial cancer:2.41e-4 (favourable)",Mixed,Tissue enhanced,,appendix: 28.5;lymph node: 49.2,tonsil: 26.8,Cell line enriched,17.0,MOLT-4: 31.3
24,CD7,"GP40, LEU-9, Tp40, TP41",ENSG00000173762,CD7 molecule,17,82314868-82317602,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002594, HPA039079",Enhanced,,,,"Renal cancer:7.75e-11 (unfavourable), Endometrial cancer:2.03e-5 (favourable), Melanoma:2.69e-4 (favourable), Cervical cancer:5.51e-4 (favourable)",Expressed in all,Tissue enhanced,,appendix: 43.1;lymph node: 41.5;spleen: 43.1,small intestine: 17.0,Group enriched,5.0,Hep G2: 35.2;MOLT-4: 95.7
25,CD70,"CD27L, CD27LG, TNFSF7",ENSG00000125726,CD70 molecule,19,6583183-6604103,"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA046582,,,Uncertain,Nucleoplasm,"Renal cancer:3.22e-4 (unfavourable), Lung cancer:6.29e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,appendix: 4.4,lymph node: 3.8,Cell line enhanced,,SiHa: 200.2;U-251 MG: 192.3;U-266/70: 304.1;U-266/84: 216.7
26,CD80,"B7-1, B7.1, CD28LG, CD28LG1",ENSG00000121594,CD80 molecule,3,119524293-119559602,"CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB025368, HPA050092",Enhanced,,,,,Mixed,Tissue enhanced,,appendix: 7.2;lymph node: 6.7;tonsil: 6.3,spleen: 4.7,Cell line enhanced,,Daudi: 8.5;HDLM-2: 39.3;Karpas-707: 12.2;U-266/70: 5.5
27,CHI3L1,"GP39, YKL40",ENSG00000133048,Chitinase 3 like 1,1,203178931-203186749,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,appendix: 186.7;cerebral cortex: 267.1;urinary bladder: 179.4,bone marrow: 146.9,Group enriched,7.0,ASC diff: 215.1;ASC TERT1: 484.9;HSkMC: 450.3;THP-1: 704.0;U-138 MG: 292.3;U-87 MG: 289.1
28,CHI3L2,"YKL-39, YKL39",ENSG00000064886,Chitinase 3 like 2,1,111200771-111243440,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA005443,Uncertain,,,,"Renal cancer:8.59e-7 (unfavourable), Glioma:1.55e-4 (unfavourable), Head and neck cancer:2.19e-4 (favourable)",Tissue enriched,Tissue enhanced,,appendix: 152.3,tonsil: 103.1,Cell line enhanced,,ASC diff: 62.1;MOLT-4: 277.3;U-698: 51.9
29,CLEC4A,"CD367, CLECSF6, DCIR, DDB27",ENSG00000111729,C-type lectin domain family 4 member A,12,8082269-8138607,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA007842,Uncertain,,,,,Expressed in all,Tissue enhanced,,appendix: 30.7,spleen: 17.1,Not detected,,
30,CLEC4E,"CLECSF9, mincle",ENSG00000166523,C-type lectin domain family 4 member E,12,8533305-8540963,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA004935,Uncertain,,Uncertain,Cytosol,,Mixed,Tissue enhanced,,appendix: 53.9;bone marrow: 49.6;spleen: 44.0,gallbladder: 18.9,Cell line enhanced,,NB-4: 2.8;RPTEC TERT1: 9.2
31,CLEC5A,"CLECSF5, MDL-1",ENSG00000258227,C-type lectin domain family 5 member A,7,141927357-141947007,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA054137,,,Supported,Plasma membrane<br>Cytosol,Ovarian cancer:2.21e-4 (unfavourable),Mixed,Tissue enhanced,,appendix: 10.6;bone marrow: 27.4,lung: 4.9,Group enriched,29.0,HL-60: 33.0;U-937: 123.1
32,CLEC6A,"CLECSF10, dectin-2",ENSG00000205846,C-type lectin domain family 6 member A,12,8455926-8478330,Predicted membrane proteins,Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,appendix: 1.5;lung: 1.5,lymph node: 0.8,Cell line enhanced,,NTERA-2: 3.3
33,CLEC7A,"CD369, CLECSF12, dectin-1, hDectin-1, SCARE2",ENSG00000172243,C-type lectin domain family 7 member A,12,10116777-10130258,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA043244, HPA050229",,,Approved,Nucleoplasm<br>Vesicles,Renal cancer:1.31e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 65.6,bone marrow: 53.3,Group enriched,15.0,Karpas-707: 144.0;U-266/84: 116.1
34,CR1,"CD35, KN",ENSG00000203710,Complement C3b/C4b receptor 1 (Knops blood group),1,207496147-207640647,"Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB002491, CAB016271, HPA042455, HPA043579, HPA049348",Enhanced,,,,,Mixed,Tissue enhanced,,appendix: 37.5;spleen: 33.6,lymph node: 23.4,Group enriched,8.0,HL-60: 7.8;HMC-1: 19.1;NB-4: 5.8
35,CRLF2,"CRL2, TSLPR",ENSG00000205755,Cytokine receptor-like factor 2,X,1187549-1212750,"Cancer-related genes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,appendix: 2.1;gallbladder: 2.0,bone marrow: 1.0,Cell line enhanced,,HMC-1: 13.5;RPMI-8226: 2.8;U-698: 2.4
36,CSF2RB,"CD131, IL3RB, IL5RB",ENSG00000100368,Colony stimulating factor 2 receptor beta common subunit,22,36913628-36940449,"CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA078677,,,Approved,Golgi apparatus,Head and neck cancer:7.47e-5 (favourable),Expressed in all,Tissue enhanced,,appendix: 89.7,tonsil: 57.2,Group enriched,7.0,HEL: 95.8;HMC-1: 281.8
37,CSF3,"C17orf33, G-CSF, GCSF, MGC45931",ENSG00000108342,Colony stimulating factor 3,17,40015361-40017813,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Endometrial cancer:8.45e-4 (favourable),Mixed,Tissue enhanced,,"appendix: 19.1;cervix, uterine: 38.2",adipose tissue: 10.3,Cell line enhanced,,BJ hTERT+: 57.2;hTEC/SVTERT24-B: 34.2;U-87 MG: 265.0
38,CSF3R,"CD114, GCSFR",ENSG00000119535,Colony stimulating factor 3 receptor,1,36466043-36483278,"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB017116, HPA048086",Enhanced,,,,"Testis cancer:3.79e-4 (unfavourable), Renal cancer:5.72e-4 (unfavourable)",Mixed,Tissue enhanced,,appendix: 211.2;bone marrow: 243.4;placenta: 147.9,spleen: 96.5,Cell line enhanced,,BEWO: 68.2;NB-4: 12.7;THP-1: 32.4;U-937: 36.3
39,CTD-2370N5.3,,ENSG00000265118,,17,31305213-31318831,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA045033,Uncertain,,,,,Not detected,Tissue enhanced,,appendix: 5.1,tonsil: 3.0,Cell line enhanced,,MOLT-4: 5.4;RPMI-8226: 3.7
40,CTD-2545M3.6,,ENSG00000142539,,19,50415799-50428409,Predicted intracellular proteins,Evidence at transcript level,HPA018523,Uncertain,,,,,Not detected,Tissue enhanced,,appendix: 1.3;spleen: 1.8,"duodenum,lymph node: 0.6",Cell line enhanced,,REH: 2.7;U-2 OS: 1.1;U-266/70: 1.2;U-698: 1.3
41,CTD-3088G3.8,,ENSG00000188897,,16,11359845-11523588,Predicted intracellular proteins,Evidence at transcript level,HPA042154,Uncertain,,,,,Not detected,Tissue enhanced,,appendix: 5.3;skin: 4.3,testis: 2.8,Cell line enhanced,,Daudi: 2.2;HDLM-2: 3.2
42,CTLA4,"CD, CD152, CELIAC3, GSE, IDDM12",ENSG00000163599,Cytotoxic T-lymphocyte associated protein 4,2,203867786-203873960,"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Head and neck cancer:4.48e-5 (favourable),Mixed,Tissue enhanced,,appendix: 23.5;lymph node: 31.9,tonsil: 15.3,Group enriched,5.0,SK-MEL-30: 2.4;U-266/70: 3.5;U-266/84: 9.7
43,CXCL10,"C7, crg-2, gIP-10, IFI10, INP10, IP-10, mob-1, SCYB10",ENSG00000169245,C-X-C motif chemokine ligand 10,4,76021117-76023497,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:1.16e-6 (unfavourable), Ovarian cancer:1.12e-5 (favourable), Pancreatic cancer:4.61e-4 (unfavourable)",Expressed in all,Tissue enhanced,,appendix: 129.4,lymph node: 72.5,Cell line enhanced,,BJ hTERT+: 4.9;BJ hTERT+ SV40 Large T+: 2.0;BJ hTERT+ SV40 Large T+ RasG12V: 2.1;RPMI-8226: 2.9;THP-1: 2.0
44,CXCL11,"b-R1, H174, I-TAC, IP-9, SCYB11, SCYB9B",ENSG00000169248,C-X-C motif chemokine ligand 11,4,76033682-76041415,Predicted secreted proteins,Evidence at protein level,CAB009921,Uncertain,,,,"Ovarian cancer:4.31e-7 (favourable), Renal cancer:3.29e-6 (unfavourable), Pancreatic cancer:8.18e-5 (unfavourable)",Expressed in all,Tissue enhanced,,appendix: 13.5,lymph node: 11.5,Group enriched,6.0,BJ hTERT+: 2.4;BJ hTERT+ SV40 Large T+: 4.3;BJ hTERT+ SV40 Large T+ RasG12V: 4.7
45,CXCL5,"ENA-78, SCYB5",ENSG00000163735,C-X-C motif chemokine ligand 5,4,73995642-73998779,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA065474,Approved,,,,"Renal cancer:2.45e-5 (unfavourable), Liver cancer:1.39e-4 (unfavourable), Pancreatic cancer:2.23e-4 (unfavourable), Cervical cancer:3.43e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,appendix: 47.7,urinary bladder: 15.5,Cell line enhanced,,A549: 165.3;EFO-21: 141.1;HSkMC: 77.3;hTEC/SVTERT24-B: 78.0;RPTEC TERT1: 436.4
46,CXCR1,"CD181, CDw128a, CKR-1, CMKAR1, IL8RA",ENSG00000163464,C-X-C motif chemokine receptor 1,2,218162845-218166995,"Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA031991,Uncertain,,,,,Mixed,Tissue enhanced,,appendix: 35.1;spleen: 25.0,adipose tissue: 15.7,Cell line enriched,32.0,HMC-1: 5.0
47,CXCR2,"CD182, CMKAR2, IL8RB",ENSG00000180871,C-X-C motif chemokine receptor 2,2,218125289-218137253,"Cancer-related genes, CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB016268, HPA031999, HPA032017",Enhanced,,,,,Mixed,Tissue enhanced,,appendix: 55.7;spleen: 36.7,esophagus: 29.9,Group enriched,10.0,BEWO: 13.6;HL-60: 6.5;HMC-1: 14.3;THP-1: 10.4;U-937: 11.8
48,CXCR5,"BLR1, CD185, MDR15",ENSG00000160683,C-X-C motif chemokine receptor 5,11,118883766-118897799,"CD markers, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB026149, HPA042432",Enhanced,,,,,Not detected,Tissue enhanced,,appendix: 14.5;lymph node: 32.5;spleen: 21.0;tonsil: 14.3,bone marrow: 6.4,Group enriched,8.0,Daudi: 12.9;U-698: 43.3
49,CYBB,"CGD, GP91-PHOX, NOX2",ENSG00000165168,Cytochrome b-245 beta chain,X,37780011-37813461,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA051227,Enhanced,,,,,Expressed in all,Tissue enhanced,,appendix: 215.6,lung: 132.2,Group enriched,5.0,Daudi: 37.3;NB-4: 40.0;REH: 49.1;RPMI-8226: 143.6
50,CYTH4,"CYT4, cytohesin-4, PSCD4",ENSG00000100055,Cytohesin 4,22,37282027-37315345,Predicted intracellular proteins,Evidence at protein level,HPA071573,Approved,,,,Renal cancer:2.41e-8 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 89.2,spleen: 69.8,Cell line enhanced,,HL-60: 27.2;HMC-1: 119.3;THP-1: 62.2
51,DENND1C,"FAM31C, FLJ22757",ENSG00000205744,DENN domain containing 1C,19,6467207-6482557,Predicted intracellular proteins,Evidence at protein level,"HPA042758, HPA042839",Enhanced,,,,"Renal cancer:7.51e-14 (favourable), Lung cancer:1.23e-4 (favourable), Urothelial cancer:5.62e-4 (favourable), Prostate cancer:8.95e-4 (unfavourable)",Expressed in all,Tissue enhanced,,appendix: 28.2;lymph node: 37.1;spleen: 31.7,bone marrow: 14.0,Cell line enhanced,,Daudi: 16.1;HEL: 13.5;HMC-1: 39.4;U-937: 24.3
52,DRD5,"DRD1B, DRD1L2",ENSG00000169676,Dopamine receptor D5,4,9781680-9784009,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA048930,Supported,,,,,Not detected,Tissue enhanced,,appendix: 1.7;cerebral cortex: 2.0;stomach: 3.8,testis: 0.8,Not detected,,
53,FCGR1B,CD64b,ENSG00000198019,Fc fragment of IgG receptor Ib,1,121087345-121096310,"FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,appendix: 27.5;epididymis: 61.7,placenta: 17.0,Cell line enhanced,,HMC-1: 6.6;NB-4: 12.8;THP-1: 51.9
54,FCGR3B,"CD16, CD16b, FCG3, FCGR3",ENSG00000162747,Fc fragment of IgG receptor IIIb,1,161623196-161631963,"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,appendix: 118.1;spleen: 115.2,urinary bladder: 36.3,Not detected,,
55,FCRL4,"CD307d, FCRH4, IGFP2, IRTA1",ENSG00000163518,Fc receptor like 4,1,157573749-157598080,"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA054030,Approved,,,,,Not detected,Tissue enhanced,,appendix: 3.6;lymph node: 4.4;tonsil: 9.6,spleen: 1.1,Cell line enriched,36.0,U-266/70: 3.5
56,FFAR2,"FFA2R, GPR43",ENSG00000126262,Free fatty acid receptor 2,19,35443907-35451767,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA023985,Approved,,,,,Tissue enhanced,Tissue enhanced,,appendix: 25.5;bone marrow: 13.3,spleen: 10.8,Cell line enhanced,,HMC-1: 3.5;U-937: 1.3
57,FFAR3,"FFA3R, GPR41",ENSG00000185897,Free fatty acid receptor 3,19,35358460-35360485,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA044681,Uncertain,,,,,Not detected,Tissue enhanced,,adipose tissue: 2.5;appendix: 3.5;smooth muscle: 2.2,gallbladder: 0.8,Not detected,,
58,FGR,"c-fgr, p55c-fgr, SRC2",ENSG00000000938,"FGR proto-oncogene, Src family tyrosine kinase",1,27612064-27635277,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA002024,Enhanced,,Approved,Plasma membrane<br>Aggresome,,Expressed in all,Tissue enhanced,,appendix: 85.6;bone marrow: 137.0;spleen: 90.6,lung: 56.3,Cell line enhanced,,Daudi: 61.4;HMC-1: 25.8;U-266/70: 116.7
59,FOXP3,"AIID, DIETER, IPEX, JM2, PIDX, SCURFIN, XPID",ENSG00000049768,Forkhead box P3,X,49250436-49264826,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB026301, HPA045943",Enhanced,,Supported,Nucleoplasm,"Cervical cancer:1.91e-4 (favourable), Head and neck cancer:4.90e-4 (favourable), Endometrial cancer:7.02e-4 (favourable)",Mixed,Tissue enhanced,,appendix: 8.7,lymph node: 6.0,Cell line enhanced,,MCF7: 2.8;SiHa: 2.3
60,FPR1,"FMLP, FPR",ENSG00000171051,Formyl peptide receptor 1,19,51745172-51804110,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA046550, HPA061744",Approved,,Approved,Nucleus<br>Nucleoli<br>Golgi apparatus,Renal cancer:2.21e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 177.8,bone marrow: 95.0,Cell line enriched,6.0,U-87 MG: 51.5
61,FPR2,"ALXR, FMLP-R-II, FMLPX, FPR2A, FPRH2, FPRL1, HM63, LXA4R",ENSG00000171049,Formyl peptide receptor 2,19,51752026-51770526,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA029154,Approved,,,,,Mixed,Tissue enhanced,,appendix: 69.7,spleen: 19.7,Cell line enriched,21.0,U-937: 23.5
62,FYB,"FYB-120/130, SLAP-130",ENSG00000082074,FYN binding protein,5,39105236-39274528,Predicted intracellular proteins,Evidence at protein level,"CAB025336, HPA026796",Enhanced,,,,Renal cancer:2.24e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 127.4;lymph node: 109.8;spleen: 114.9,tonsil: 64.3,Cell line enhanced,,HEL: 61.3;MOLT-4: 171.5;REH: 58.5;U-937: 68.8
63,GAL,"GAL-GMAP, GALN, GLNN, GMAP",ENSG00000069482,Galanin and GMAP prepropeptide,11,68683779-68691175,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA049864,Enhanced,Supported,Approved,Golgi apparatus<br>Vesicles,"Endometrial cancer:1.22e-4 (unfavourable), Lung cancer:8.17e-4 (unfavourable)",Mixed,Tissue enhanced,,appendix: 18.1;smooth muscle: 12.1,colon: 5.2,Cell line enhanced,,CACO-2: 193.9;K-562: 111.4;NB-4: 277.5;SH-SY5Y: 179.1
64,GAPT,"C5orf29, FLJ33641",ENSG00000175857,"GRB2 binding adaptor protein, transmembrane",5,58491435-58497090,Predicted intracellular proteins,Evidence at protein level,HPA011070,Uncertain,,,,,Mixed,Tissue enhanced,,appendix: 38.8;tonsil: 38.8,lymph node: 30.1,Cell line enhanced,,HEL: 64.1;HL-60: 33.1;NB-4: 27.3;THP-1: 22.7;U-937: 92.5
65,GBP5,,ENSG00000154451,Guanylate binding protein 5,1,89258950-89272804,Predicted intracellular proteins,Evidence at protein level,HPA028656,Approved,,Approved,Endoplasmic reticulum,"Renal cancer:5.53e-8 (unfavourable), Endometrial cancer:3.73e-6 (favourable), Ovarian cancer:1.24e-4 (favourable), Colorectal cancer:9.54e-4 (favourable)",Expressed in all,Tissue enhanced,,appendix: 100.5,lymph node: 60.4,Cell line enhanced,,NB-4: 6.3;U-266/70: 15.8;U-937: 24.8
66,GPR171,H963,ENSG00000174946,G protein-coupled receptor 171,3,151197832-151203201,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA062429,Approved,,,,,Mixed,Tissue enhanced,,appendix: 29.8,lymph node: 21.5,Cell line enriched,21.0,U-266/70: 21.2
67,GPR84,EX33,ENSG00000139572,G protein-coupled receptor 84,12,54362445-54364487,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA027603,Enhanced,,,,,Mixed,Tissue enhanced,,appendix: 11.6;bone marrow: 14.7,adipose tissue: 6.0,Cell line enhanced,,HL-60: 10.3;NB-4: 25.5;U-937: 4.0
68,HAPLN3,"EXLD1, HsT19883",ENSG00000140511,Hyaluronan and proteoglycan link protein 3,15,88877288-88895626,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA039237,Uncertain,,Approved,Plasma membrane<br>Cytosol,Renal cancer:4.18e-13 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 13.8;lymph node: 10.8,spleen: 4.0,Cell line enhanced,,HDLM-2: 29.8;U-2 OS: 31.7
69,HCK,JTK9,ENSG00000101336,"HCK proto-oncogene, Src family tyrosine kinase",20,32052188-32101856,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB005195, HPA063768",Approved,,Approved,Nucleoplasm<br>Plasma membrane,Renal cancer:1.66e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 149.6;spleen: 113.2,lung: 74.1,Group enriched,8.0,THP-1: 48.4;U-937: 161.1
70,IER3,"DIF-2, IEX-1, IEX-1L, PRG1",ENSG00000137331,Immediate early response 3,6,30743199-30744554,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA043847,Approved,,,,"Renal cancer:3.10e-7 (unfavourable), Liver cancer:6.36e-5 (unfavourable), Head and neck cancer:5.57e-4 (unfavourable)",Expressed in all,Tissue enhanced,,appendix: 20.7,adipose tissue: 11.4,Group enriched,6.0,A-431: 133.8;EFO-21: 51.6;HBEC3-KT: 133.4;RPTEC TERT1: 150.4
71,IFNG,,ENSG00000111537,Interferon gamma,12,68154768-68159747,"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,CAB010344,Approved,,,,,Mixed,Tissue enhanced,,appendix: 4.7;bone marrow: 7.6;lymph node: 7.9,lung: 2.5,Not detected,,
72,IGSF6,DORA,ENSG00000140749,Immunoglobulin superfamily member 6,16,21639537-21652660,Predicted membrane proteins,Evidence at protein level,"HPA041023, HPA041072",Uncertain,,,,"Endometrial cancer:1.54e-5 (favourable), Cervical cancer:4.92e-4 (favourable)",Expressed in all,Tissue enhanced,,appendix: 15.2;spleen: 18.1,lung: 8.0,Not detected,,
73,IL10,"CSIF, IL-10, IL10A, TGIF",ENSG00000136634,Interleukin 10,1,206767602-206772494,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,CAB013120,Uncertain,,,,,Mixed,Tissue enhanced,,appendix: 8.7,adipose tissue: 7.4,Group enriched,7.0,HMC-1: 5.2;U-266/70: 6.5
74,IL11,"AGIF, IL-11",ENSG00000095752,Interleukin 11,19,55364389-55370463,"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA044955,,,Uncertain,Mitochondria,Pancreatic cancer:7.50e-4 (unfavourable),Mixed,Tissue enhanced,,appendix: 5.7;endometrium: 5.2;gallbladder: 4.9,placenta: 1.7,Cell line enhanced,,BJ: 50.3;BJ hTERT+: 54.5;hTEC/SVTERT24-B: 54.2;U-251 MG: 179.7
75,IL17A,"CTLA8, IL-17, IL-17A, IL17",ENSG00000112115,Interleukin 17A,6,52186387-52190638,"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA052258,Uncertain,,,,,Not detected,Tissue enhanced,,appendix: 1.0;tonsil: 1.3;urinary bladder: 1.5,gallbladder: 0.3,Group enriched,16.0,Karpas-707: 1.9;U-266/84: 1.2
76,IL17REL,FLJ41993,ENSG00000188263,Interleukin 17 receptor E like,22,49994513-50012659,Predicted intracellular proteins,Evidence at protein level,HPA045546,Supported,,,,,Mixed,Tissue enhanced,,appendix: 3.1;lymph node: 2.4;tonsil: 4.0,stomach: 2.1,Not detected,,
77,IL1B,"IL-1B, IL1-BETA, IL1F2",ENSG00000125538,Interleukin 1 beta,2,112829751-112836903,"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:7.49e-5 (unfavourable), Cervical cancer:1.31e-4 (unfavourable)",Mixed,Tissue enhanced,,appendix: 68.0;bone marrow: 106.4,adipose tissue: 53.4,Cell line enhanced,,BJ hTERT+: 478.0;HBEC3-KT: 193.4;HMC-1: 189.1;hTEC/SVTERT24-B: 291.2;U-87 MG: 514.6
78,IL21R,CD360,ENSG00000103522,Interleukin 21 receptor,16,27402162-27452042,"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA042296,Uncertain,,Uncertain,Plasma membrane<br>Cytosol,Head and neck cancer:7.29e-4 (favourable),Mixed,Tissue enhanced,,appendix: 15.8;lymph node: 28.8;tonsil: 17.4,spleen: 7.5,Cell line enhanced,,HDLM-2: 102.6;Karpas-707: 35.4;RH-30: 36.0;RPMI-8226: 42.7
79,IL24,"C49A, FISP, IL-24, IL10B, mda-7, Mob-5, ST16",ENSG00000162892,Interleukin 24,1,206897443-206904139,"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB025972,Uncertain,,,,Breast cancer:5.09e-4 (favourable),Mixed,Tissue enhanced,,appendix: 17.3;lymph node: 37.1;spleen: 23.4,urinary bladder: 5.4,Cell line enriched,10.0,BJ hTERT+: 144.5
80,IL26,"AK155, IL-26",ENSG00000111536,Interleukin 26,12,68201351-68225821,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,appendix: 1.2;urinary bladder: 1.4,tonsil: 0.9,Cell line enriched,19.0,HDLM-2: 12.4
81,IL2RA,"CD25, IDDM10, IL2R",ENSG00000134460,Interleukin 2 receptor subunit alpha,10,6010689-6062325,"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB002419, HPA054622",Enhanced,,,,Renal cancer:2.08e-9 (unfavourable),Mixed,Tissue enhanced,,adipose tissue: 24.2;appendix: 19.8;lymph node: 20.4,tonsil: 12.0,Cell line enriched,80.0,HDLM-2: 1041.6
82,IL4I1,FIG1,ENSG00000104951,Interleukin 4 induced 1,19,49889654-49929539,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA045598,Enhanced,,,,"Renal cancer:1.23e-10 (unfavourable), Glioma:1.85e-4 (unfavourable)",Expressed in all,Tissue enhanced,,appendix: 24.5;testis: 32.0,lymph node: 10.5,Cell line enhanced,,EFO-21: 31.1;HDLM-2: 55.9;Karpas-707: 33.8
83,IL7R,CD127,ENSG00000168685,Interleukin 7 receptor,5,35852695-35879603,"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB010215,Approved,,Approved,Plasma membrane<br>Microtubule organizing center,,Expressed in all,Tissue enhanced,,appendix: 182.9;lymph node: 158.5,tonsil: 112.9,Cell line enhanced,,fHDF/TERT166: 149.9;HBF TERT88: 165.6;REH: 372.0
84,ITGAX,CD11C,ENSG00000140678,Integrin subunit alpha X,16,31355134-31382997,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB004458, HPA004723, CAB072871",Enhanced,,,,Renal cancer:1.37e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 58.3;spleen: 59.0,bone marrow: 30.4,Cell line enriched,5.0,HMC-1: 92.2
85,ITK,"EMT, LYK, PSCTK2",ENSG00000113263,IL2 inducible T-cell kinase,5,157142933-157255191,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,appendix: 20.2;lymph node: 33.2;tonsil: 22.3,spleen: 14.0,Cell line enhanced,,HDLM-2: 3.2;HEL: 3.4;HMC-1: 3.8;MOLT-4: 18.7
86,JAK3,"JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK",ENSG00000105639,Janus kinase 3,19,17824780-17848071,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA070314,Enhanced,,,,"Renal cancer:2.89e-14 (unfavourable), Cervical cancer:6.42e-5 (favourable)",Expressed in all,Tissue enhanced,,appendix: 48.4;lymph node: 46.6,tonsil: 27.2,Cell line enhanced,,HDLM-2: 33.0;Karpas-707: 28.7;U-266/84: 17.1;U-937: 18.8
87,JAML,"AMICA, AMICA1, Gm638",ENSG00000160593,Junction adhesion molecule like,11,118193740-118225094,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA047919,Approved,,,,"Head and neck cancer:3.11e-4 (favourable), Lung cancer:3.92e-4 (favourable)",Mixed,Tissue enhanced,,appendix: 82.3,spleen: 67.0,Cell line enhanced,,CACO-2: 4.8;HMC-1: 24.2
88,LILRA5,"CD85, CD85f, ILT11, LILRB7, LIR9",ENSG00000187116,Leukocyte immunoglobulin like receptor A5,19,54307070-54313139,"CD markers, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:7.78e-4 (unfavourable),Mixed,Tissue enhanced,,appendix: 13.9;bone marrow: 10.3;spleen: 7.5,urinary bladder: 2.4,Not detected,,
89,LILRA6,"CD85b, ILT8, LILRB6",ENSG00000244482,Leukocyte immunoglobulin like receptor A6,19,54236592-54242791,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,adipose tissue: 1.9;appendix: 1.9;smooth muscle: 1.9;spleen: 1.9,bone marrow: 1.0,Not detected,,
90,LILRB1,"CD85, CD85j, ILT2, LIR-1, LIR1, MIR-7, PIR-B, PIRB",ENSG00000104972,Leukocyte immunoglobulin like receptor B1,19,54617158-54637528,Predicted membrane proteins,Evidence at transcript level,,,,,,Renal cancer:3.08e-6 (unfavourable),Mixed,Tissue enhanced,,appendix: 8.6;lymph node: 6.2;spleen: 9.9,smooth muscle: 3.7,Group enriched,17.0,Daudi: 4.0;THP-1: 1.9
91,LILRB2,"CD85d, ILT4, LIR-2, LIR2, MIR-10, MIR10",ENSG00000131042,Leukocyte immunoglobulin like receptor B2,19,54273821-54281184,"CD markers, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:5.45e-7 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 8.7;bone marrow: 20.5;spleen: 10.4,lung: 3.9,Not detected,,
92,LILRB4,"CD85k, HM18, ILT3, LIR-5, LIR5",ENSG00000186818,Leukocyte immunoglobulin like receptor B4,19,54643889-54670359,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA052807,Approved,,,,,Expressed in all,Tissue enhanced,,appendix: 14.6;lymph node: 13.4,lung: 8.3,Cell line enriched,33.0,Karpas-707: 293.0
93,LINGO3,"LERN2, LRRN6B",ENSG00000220008,Leucine rich repeat and Ig domain containing 3,19,2289784-2292024,Predicted membrane proteins,Evidence at protein level,"HPA043781, HPA055932, HPA059558",Uncertain,,Approved,Mitochondria,,Tissue enhanced,Tissue enhanced,,appendix: 1.6;cerebral cortex: 1.6;spleen: 3.7,lymph node: 1.2,Group enriched,6.0,HMC-1: 15.2;RPMI-8226: 3.0
94,LRRC25,"FLJ38116, MAPA",ENSG00000175489,Leucine rich repeat containing 25,19,18391144-18397617,Predicted membrane proteins,Evidence at protein level,HPA029459,Approved,,,,Testis cancer:6.93e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 30.4;spleen: 40.6,bone marrow: 20.7,Cell line enhanced,,HMC-1: 1.6;THP-1: 1.2;U-937: 1.1
95,MADCAM1,MACAM1,ENSG00000099866,Mucosal vascular addressin cell adhesion molecule 1,19,489176-505342,Predicted membrane proteins,Evidence at protein level,CAB075699,Enhanced,,,,,Mixed,Tissue enhanced,,appendix: 17.8;spleen: 11.4,gallbladder: 3.3,Mixed,,
96,MARCO,SCARA2,ENSG00000019169,Macrophage receptor with collagenous structure,2,118942166-118994660,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA063793,Enhanced,,Approved,Golgi apparatus<br>Vesicles,,Mixed,Tissue enhanced,,appendix: 123.2;lung: 288.2,adipose tissue: 78.0,Cell line enhanced,,HaCaT: 1.5;THP-1: 1.7;U-2 OS: 2.7;U-266/70: 1.1
97,MEFV,"FMF, MEF, TRIM20",ENSG00000103313,"MEFV, pyrin innate immunity regulator",16,3242028-3256627,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,appendix: 8.1;spleen: 7.0,bone marrow: 4.2,Cell line enhanced,,THP-1: 4.4
98,MMP1,CLG,ENSG00000196611,Matrix metallopeptidase 1,11,102789920-102798160,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA004920,,,Approved,Vesicles,"Renal cancer:9.86e-10 (unfavourable), Liver cancer:4.22e-6 (unfavourable), Cervical cancer:4.66e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,appendix: 39.2;gallbladder: 126.4,urinary bladder: 29.1,Cell line enhanced,,BJ hTERT+: 921.1;HBF TERT88: 1061.5;HUVEC TERT2: 2464.5;WM-115: 1436.5
99,MMP12,HME,ENSG00000262406,Matrix metallopeptidase 12,11,102862736-102875034,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,,,,,,Liver cancer:1.42e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 54.6;urinary bladder: 28.7,tonsil: 17.3,Group enriched,11.0,BJ: 2.7;fHDF/TERT166: 8.5;hTEC/SVTERT24-B: 6.1
100,MMP25,"MMP20, MMPL1, MT6-MMP",ENSG00000008516,Matrix metallopeptidase 25,16,3046681-3060726,"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB025177,Uncertain,,,,Head and neck cancer:1.09e-5 (favourable),Tissue enhanced,Tissue enhanced,,appendix: 23.3;bone marrow: 24.7;spleen: 20.7,adipose tissue: 6.4,Cell line enriched,11.0,HMC-1: 95.7
101,MMP3,"STMY, STMY1",ENSG00000149968,Matrix metallopeptidase 3,11,102835801-102843803,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA007875,Uncertain,,Supported,Vesicles,"Pancreatic cancer:4.09e-4 (unfavourable), Cervical cancer:9.73e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,appendix: 26.5;endometrium: 58.6,urinary bladder: 9.0,Group enriched,15.0,BJ: 1172.2;BJ hTERT+: 3041.4;fHDF/TERT166: 1276.8
102,MYO1F,,ENSG00000142347,Myosin IF,19,8520790-8577577,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA055242,Enhanced,,,,Renal cancer:3.27e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 50.4;bone marrow: 59.7;spleen: 63.3,lung: 23.4,Cell line enhanced,,HDLM-2: 45.8;HMC-1: 73.1;NB-4: 127.9;THP-1: 99.8;U-937: 61.8
103,NFAM1,CNAIP,ENSG00000235568,NFAT activating protein with ITAM motif 1,22,42380410-42432395,Predicted membrane proteins,Evidence at protein level,HPA031812,Uncertain,,,,Endometrial cancer:6.16e-4 (favourable),Expressed in all,Tissue enhanced,,appendix: 17.2;bone marrow: 20.2,spleen: 14.5,Cell line enhanced,,NB-4: 5.5;SCLC-21H: 6.8;THP-1: 25.4
104,NLRC4,"CARD12, CLAN, CLAN1, CLANA, CLANB, CLANC, CLAND, CLR2.1, ipaf",ENSG00000091106,NLR family CARD domain containing 4,2,32224453-32265854,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA006592,Uncertain,,,,,Mixed,Tissue enhanced,,appendix: 12.4,lung: 9.3,Cell line enhanced,,HL-60: 2.4
105,NLRP12,"CLR19.3, Monarch1, NALP12, PAN6, PYPAF7, RNO2",ENSG00000142405,NLR family pyrin domain containing 12,19,53793603-53824394,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA042981,Approved,,,,,Tissue enriched,Tissue enhanced,,appendix: 3.1;bone marrow: 4.1,spleen: 2.2,Cell line enhanced,,HMC-1: 3.9;THP-1: 2.7;U-87 MG: 4.2;U-937: 2.9
106,NOXO1,"P41NOXA, P41NOXB, P41NOXC, SH3PXD5, SNX28",ENSG00000196408,NADPH oxidase organizer 1,16,1978917-1984192,"FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA071540,Enhanced,,,,,Not detected,Tissue enhanced,,appendix: 6.3;colon: 7.4;rectum: 6.5,duodenum: 3.3,Cell line enhanced,,CAPAN-2: 2.4;HaCaT: 1.4;SCLC-21H: 1.6
107,PANK4,FLJ10782,ENSG00000157881,Pantothenate kinase 4,1,2508533-2526628,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA011723, HPA012036, HPA027961",Uncertain,,Approved,Cytosol,Renal cancer:1.57e-5 (favourable),Expressed in all,Tissue enhanced,,appendix: 3.2,skin: 2.9,Mixed,,
108,PI15,P25TI,ENSG00000137558,Peptidase inhibitor 15,8,74824537-74855029,Predicted secreted proteins,Evidence at protein level,"HPA006593, HPA030057",Uncertain,,Approved,Vesicles<br>Cytosol,,Group enriched,Tissue enhanced,,appendix: 73.2;prostate: 50.5;smooth muscle: 67.8,endometrium: 33.0,Group enriched,9.0,AF22: 21.0;SH-SY5Y: 22.2;SK-MEL-30: 22.4;U-266/70: 5.5
109,PILRA,FDF03,ENSG00000085514,Paired immunoglobin like type 2 receptor alpha,7,100367530-100400099,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA056132,Approved,,,,"Renal cancer:1.61e-4 (unfavourable), Cervical cancer:2.99e-4 (favourable)",Expressed in all,Tissue enhanced,,appendix: 52.4,lung: 43.8,Cell line enhanced,,ASC diff: 18.7;HMC-1: 21.9;NB-4: 12.4
110,PROK2,"BV8, KAL4, MIT1, PK2",ENSG00000163421,Prokineticin 2,3,71771656-71785206,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA041408,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,appendix: 30.3;bone marrow: 52.7;testis: 24.1,adipose tissue: 11.2,Group enriched,5.0,HL-60: 8.9;NB-4: 6.1;NTERA-2: 6.5;U-266/70: 11.1;U-266/84: 17.7;U-937: 7.9
111,PTAFR,,ENSG00000169403,Platelet activating factor receptor,1,28147166-28193936,"G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA027543,Approved,,Supported,Nucleoplasm<br>Vesicles<br>Plasma membrane,,Expressed in all,Tissue enhanced,,appendix: 41.1,bone marrow: 26.2,Cell line enhanced,,HBEC3-KT: 26.0;HMC-1: 113.4
112,PTPRCAP,"CD45-AP, LPAP",ENSG00000213402,"Protein tyrosine phosphatase, receptor type C associated protein",11,67435510-67438067,Predicted secreted proteins,Evidence at protein level,HPA043734,Enhanced,,,,,Not detected,Tissue enhanced,,appendix: 64.0;lymph node: 91.4;spleen: 84.9,tonsil: 29.0,Cell line enhanced,,Daudi: 161.8;HDLM-2: 148.3;MOLT-4: 110.0;NB-4: 409.0;U-698: 109.1
113,PTX3,"TNFAIP5, TSG-14",ENSG00000163661,Pentraxin 3,3,157436789-157443628,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA069320,Approved,,,,"Endometrial cancer:8.35e-9 (unfavourable), Lung cancer:8.75e-6 (unfavourable), Head and neck cancer:6.36e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,adipose tissue: 164.6;appendix: 54.2,bone marrow: 52.6,Cell line enhanced,,ASC TERT1: 1187.1;HHSteC: 1837.3;HSkMC: 1660.2;hTEC/SVTERT24-B: 1235.3;TIME: 1387.2;U-2197: 1444.5
114,RP11-231C18.3,,ENSG00000282278,,4,53377839-54295272,Predicted intracellular proteins,Evidence at protein level,HPA058202,,,,,,,Tissue enhanced,,appendix: 1.2;cerebral cortex: 3.3,"ovary,smooth muscle: 0.7",Cell line enhanced,,BJ hTERT+: 2.8;fHDF/TERT166: 6.4;HDLM-2: 2.1;NTERA-2: 1.8;U-2197: 1.7
115,RP4-576H24.4,,ENSG00000260861,,20,1540144-1620009,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,appendix: 3.3;cerebral cortex: 4.5,testis: 2.5,Cell line enhanced,,HL-60: 2.6;HMC-1: 5.9;NB-4: 1.4;THP-1: 1.8;U-937: 1.5
116,RP4-583P15.15,,ENSG00000273154,,20,63708864-63739103,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,adrenal gland: 1.2;appendix: 1.0,"duodenum,prostate: 0.5",Mixed,,
117,SAMSN1,"HACS1, NASH1, SASH2, SH3D6B, SLy2",ENSG00000155307,"SAM domain, SH3 domain and nuclear localization signals 1",21,14485228-14583402,Predicted intracellular proteins,Evidence at protein level,"HPA010645, HPA017055",Approved,,Enhanced,Plasma membrane,Renal cancer:4.52e-6 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 110.1;bone marrow: 123.6,spleen: 43.6,Cell line enhanced,,HEL: 244.0;K-562: 292.8;Karpas-707: 97.1
118,SH2D2A,"F2771, TSAd",ENSG00000027869,SH2 domain containing 2A,1,156806243-156816862,Predicted intracellular proteins,Evidence at protein level,,,,,,"Renal cancer:5.26e-12 (unfavourable), Urothelial cancer:1.31e-4 (favourable), Breast cancer:4.96e-4 (favourable)",Expressed in all,Tissue enhanced,,appendix: 15.0,lymph node: 10.5,Cell line enhanced,,HDLM-2: 42.7;HMC-1: 29.0;Karpas-707: 57.7
119,SIGLEC10,"MGC126774, PRO940, SIGLEC-10, SLG2",ENSG00000142512,Sialic acid binding Ig like lectin 10,19,51410021-51417803,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB025807, HPA027093",Enhanced,,Supported,Plasma membrane<br>Actin filaments<br>Cytosol,Renal cancer:4.74e-5 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 48.4;spleen: 36.9,lymph node: 22.1,Cell line enhanced,,Daudi: 21.0;HEL: 13.5;HMC-1: 10.2;U-698: 14.8;U-937: 9.7
120,SIGLEC12,"S2V, Siglec-12, Siglec-L1, Siglec-XII, SIGLECL1, SLG",ENSG00000254521,Sialic acid binding Ig like lectin 12 (gene/pseudogene),19,51491357-51501789,Predicted membrane proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,appendix: 6.4;spleen: 12.8,smooth muscle: 3.7,Group enriched,9.0,HMC-1: 124.2;U-937: 61.4
121,SIGLEC14,,ENSG00000254415,Sialic acid binding Ig like lectin 14,19,51642553-51646801,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA014377,Uncertain,,,,,Mixed,Tissue enhanced,,appendix: 34.8;spleen: 55.2,bone marrow: 18.3,Group enriched,10.0,HMC-1: 87.0;U-937: 19.3
122,SIGLEC5,"CD170, CD33L2, OB-BP2, SIGLEC-5",ENSG00000105501,Sialic acid binding Ig like lectin 5,19,51611927-51645545,"CD markers, Predicted membrane proteins",Evidence at protein level,"HPA009085, CAB024900",Supported,,,,,Tissue enhanced,Tissue enhanced,,appendix: 9.3;bone marrow: 9.7;spleen: 8.8,lymph node: 3.5,Group enriched,7.0,HMC-1: 52.0;U-937: 19.9
123,SIGLEC9,CD329,ENSG00000129450,Sialic acid binding Ig like lectin 9,19,51124908-51136651,Predicted membrane proteins,Evidence at protein level,HPA010682,Uncertain,,,,Renal cancer:6.17e-5 (unfavourable),Mixed,Tissue enhanced,,appendix: 24.7;spleen: 23.5,lung: 12.2,Group enriched,7.0,Karpas-707: 16.8;RPMI-8226: 11.4
124,SIRPB1,"CD172b, SIRP-BETA-1",ENSG00000101307,Signal regulatory protein beta 1,20,1563521-1620061,"CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA047463,Uncertain,,Uncertain,Vesicles,,Mixed,Tissue enhanced,,appendix: 38.7;bone marrow: 33.7,lung: 28.0,Cell line enhanced,,HMC-1: 46.6;NB-4: 46.7;THP-1: 38.2
125,SIRPB2,"dJ776F14.2, PTPN1L, PTPNS1L3",ENSG00000196209,Signal regulatory protein beta 2,20,1470741-1491587,Predicted membrane proteins,Evidence at protein level,"HPA011548, HPA048032",Uncertain,,Approved,Nuclear bodies,,Mixed,Tissue enhanced,,appendix: 17.0,placenta: 10.9,Cell line enhanced,,A-431: 4.2;HMC-1: 7.0;hTCEpi: 6.2;THP-1: 5.3;U-937: 6.6
126,SLA,"hSLAP, SLA1, SLAP, SLAP-1",ENSG00000155926,Src like adaptor,8,133036724-133103054,Predicted intracellular proteins,Evidence at protein level,"HPA012296, HPA074192",Approved,,Approved,Nuclear membrane,,Expressed in all,Tissue enhanced,,appendix: 104.2,lymph node: 79.7,Cell line enhanced,,HMC-1: 39.6;Karpas-707: 88.0;MOLT-4: 27.3;U-266/84: 51.3;U-937: 38.7
127,SLAMF1,"CD150, SLAM",ENSG00000117090,Signaling lymphocytic activation molecule family member 1,1,160608100-160647295,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB002438, HPA069319",Enhanced,,,,,Mixed,Tissue enhanced,,appendix: 15.4;lymph node: 21.1;tonsil: 14.3,spleen: 7.9,Cell line enriched,134.0,HDLM-2: 142.1
128,SLAMF8,"BLAME, CD353, SBBI42",ENSG00000158714,SLAM family member 8,1,159826750-159837249,"CD markers, Predicted membrane proteins",Evidence at protein level,HPA067601,Enhanced,,,,Renal cancer:5.42e-5 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 39.3,lymph node: 36.1,Cell line enhanced,,ASC TERT1: 1.1;HL-60: 1.0;U-138 MG: 2.0;U-87 MG: 1.3
129,SLC11A1,"LSH, NRAMP, NRAMP1",ENSG00000018280,Solute carrier family 11 member 1,2,218382029-218396894,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA029590,Uncertain,,,,Renal cancer:2.58e-8 (unfavourable),Mixed,Tissue enhanced,,appendix: 9.1;lung: 13.0,spleen: 4.6,Not detected,,
130,SOCS1,"Cish1, JAB, SOCS-1, SSI-1, TIP3",ENSG00000185338,Suppressor of cytokine signaling 1,16,11254405-11256179,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB010355, HPA074108",Approved,,Supported,Nucleoplasm<br>Cytoplasmic bodies,"Renal cancer:1.08e-6 (unfavourable), Head and neck cancer:1.10e-4 (favourable)",Expressed in all,Tissue enhanced,,appendix: 19.3,lymph node: 15.7,Cell line enriched,6.0,HDLM-2: 102.4
131,SPIB,SPI-B,ENSG00000269404,Spi-B transcription factor,19,50418938-50431313,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA018523,Uncertain,,,,"Head and neck cancer:2.14e-5 (favourable), Breast cancer:4.76e-5 (favourable)",Mixed,Tissue enhanced,,appendix: 53.9;lymph node: 103.3;tonsil: 91.1,spleen: 39.2,Group enriched,10.0,Daudi: 119.1;HDLM-2: 99.4;Karpas-707: 37.4;U-698: 159.1
132,TIFAB,,ENSG00000255833,TIFA inhibitor,5,135444218-135452399,Predicted intracellular proteins,Evidence at protein level,HPA049372,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,appendix: 4.9;lymph node: 6.3,tonsil: 4.5,Group enriched,14.0,THP-1: 6.0;U-937: 1.5
133,TLR2,"CD282, TIL4",ENSG00000137462,Toll like receptor 2,4,153701500-153705699,"CD markers, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"HPA060231, HPA071546",,,Supported,Nucleus<br>Mitochondria,Renal cancer:1.11e-4 (unfavourable),Expressed in all,Tissue enhanced,,appendix: 52.7,bone marrow: 34.8,Cell line enhanced,,RT4: 8.5;THP-1: 25.3
134,TLR8,CD288,ENSG00000101916,Toll like receptor 8,X,12906620-12923169,"CD markers, Predicted membrane proteins",Evidence at protein level,HPA001608,Enhanced,,,,,Mixed,Tissue enhanced,,appendix: 23.2;lung: 15.6;spleen: 18.3,lymph node: 6.6,Not detected,,
135,TNC,"DFNA56, HXB, MGC167029, TN",ENSG00000041982,Tenascin C,9,115019578-115118257,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB004592, HPA004823",Approved,,,,,Expressed in all,Tissue enhanced,,appendix: 239.3;smooth muscle: 528.9,adipose tissue: 78.7,Cell line enhanced,,BJ hTERT+: 628.6;hTEC/SVTERT24-B: 625.8;U-87 MG: 679.1;WM-115: 1198.9
136,TNFAIP6,"TSG-6, TSG6",ENSG00000123610,TNF alpha induced protein 6,2,151357592-151380048,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB032719, HPA050884",Approved,,,,"Cervical cancer:8.18e-5 (unfavourable), Urothelial cancer:9.16e-5 (unfavourable), Renal cancer:5.59e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,appendix: 38.7;gallbladder: 31.8,adipose tissue: 18.7,Cell line enhanced,,BJ hTERT+: 54.6;HHSteC: 33.8;hTEC/SVTERT24-B: 54.8;U-2197: 41.1
137,TNFRSF10C,"CD263, DcR1, LIT, TRAILR3, TRID",ENSG00000173535,TNF receptor superfamily member 10c,8,23084355-23117437,"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB025635,Enhanced,,,,,Mixed,Tissue enhanced,,appendix: 21.9,spleen: 18.2,Group enriched,5.0,BEWO: 78.5;HUVEC TERT2: 56.8
138,TNFRSF1B,"CD120b, p75, TNF-R-II, TNF-R75, TNFBR, TNFR2, TNFR80",ENSG00000028137,TNF receptor superfamily member 1B,1,12167003-12209228,"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA004796,Approved,,,,"Renal cancer:8.35e-5 (unfavourable), Testis cancer:8.68e-4 (unfavourable)",Expressed in all,Tissue enhanced,,appendix: 100.4,spleen: 77.8,Cell line enhanced,,CAPAN-2: 31.7;K-562: 41.3;THP-1: 35.7;U-87 MG: 34.0
139,TNFRSF4,"ACT35, CD134, OX40, TXGP1L",ENSG00000186827,TNF receptor superfamily member 4,1,1211326-1214138,"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins",Evidence at protein level,CAB016128,Enhanced,,,,"Head and neck cancer:3.50e-6 (favourable), Renal cancer:4.52e-6 (unfavourable), Liver cancer:6.03e-4 (unfavourable)",Expressed in all,Tissue enhanced,,adipose tissue: 9.7;appendix: 8.3,lymph node: 7.1,Group enriched,8.0,MOLT-4: 5.0;NB-4: 7.6
140,TNFRSF8,"CD30, D1S166E, KI-1",ENSG00000120949,TNF receptor superfamily member 8,1,12063377-12144207,"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB000016, HPA032081, HPA032082",Approved,,,,,Tissue enriched,Tissue enhanced,,appendix: 4.1,adipose tissue: 3.1,Cell line enriched,22.0,HDLM-2: 528.2
141,TNIP3,"ABIN-3, FLJ21162, LIND",ENSG00000050730,TNFAIP3 interacting protein 3,4,121131408-121227466,Predicted intracellular proteins,Evidence at protein level,HPA043063,Uncertain,,,,,Mixed,Tissue enhanced,,appendix: 8.8,"lymph node,tonsil: 2.9",Cell line enhanced,,HDLM-2: 6.8;hTEC/SVTERT24-B: 8.0;U-138 MG: 30.3;U-266/70: 6.7;U-266/84: 6.5
142,TRAT1,"HSPC062, TCRIM, TRIM",ENSG00000163519,T-cell receptor associated transmembrane adaptor 1,3,108822698-108855005,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA002356, CAB026130",Enhanced,,,,,Mixed,Tissue enhanced,,appendix: 14.0;lymph node: 26.4,spleen: 11.5,Cell line enriched,39.0,MOLT-4: 58.7
143,TREM1,"CD354, TREM-1",ENSG00000124731,Triggering receptor expressed on myeloid cells 1,6,41267926-41286719,"CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA005563,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,appendix: 67.7;bone marrow: 63.0;lung: 103.1,adipose tissue: 26.9,Cell line enriched,11.0,U-87 MG: 24.5
144,TREML2,"C6orf76, dJ238O23.1, FLJ13693, TLT2",ENSG00000112195,Triggering receptor expressed on myeloid cells like 2,6,41190277-41201194,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,appendix: 9.3;bone marrow: 10.0;lymph node: 11.9,spleen: 8.8,Cell line enhanced,,HEL: 26.9;HL-60: 5.6;U-698: 5.8;U-937: 4.3
145,TYMP,"ECGF1, MNGIE",ENSG00000025708,Thymidine phosphorylase,22,50525752-50530056,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA000530, HPA001072, CAB002518",Enhanced,,Approved,Nuclear bodies<br>Golgi apparatus,"Renal cancer:3.50e-8 (unfavourable), Endometrial cancer:4.34e-5 (favourable)",Expressed in all,Tissue enhanced,,appendix: 100.6,spleen: 53.1,Cell line enhanced,,CAPAN-2: 37.3;HHSteC: 84.7;Karpas-707: 72.1;U-266/70: 36.4
146,VCAN,"CSPG2, PG-M",ENSG00000038427,Versican,5,83471465-83582303,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA004726, CAB008979",Enhanced,,Supported,Vesicles,"Stomach cancer:1.41e-4 (unfavourable), Renal cancer:5.17e-4 (unfavourable), Melanoma:7.59e-4 (unfavourable)",Expressed in all,Tissue enhanced,,appendix: 105.5;placenta: 104.6,smooth muscle: 67.1,Cell line enhanced,,AF22: 296.8;RPTEC TERT1: 288.7;U-2197: 156.9
147,WAS,"IMD2, THC, WASP, WASPA",ENSG00000015285,Wiskott-Aldrich syndrome,X,48676596-48691427,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA002022, CAB004290",Enhanced,,,,"Renal cancer:5.58e-6 (unfavourable), Head and neck cancer:3.78e-4 (favourable), Endometrial cancer:4.95e-4 (favourable)",Expressed in all,Tissue enhanced,,appendix: 69.0;lymph node: 60.8;spleen: 68.8,bone marrow: 37.5,Cell line enhanced,,HMC-1: 135.1;U-937: 66.6
148,XXbac-BPG246D15.9,,ENSG00000250264,,6,32813767-32838822,Predicted membrane proteins,Evidence at transcript level,HPA001312,Approved,,Approved,Nuclear speckles<br>Endoplasmic reticulum,,Not detected,Tissue enhanced,,appendix: 15.5;spleen: 9.5,lymph node: 6.5,Cell line enhanced,,Daudi: 14.2;HDLM-2: 12.4;HEL: 12.9
149,ZAP70,"SRK, STD, ZAP-70",ENSG00000115085,Zeta chain of T-cell receptor associated protein kinase 70,2,97713560-97739862,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB002625, HPA003134",Enhanced,,,,"Renal cancer:3.02e-8 (unfavourable), Endometrial cancer:9.66e-8 (favourable), Head and neck cancer:3.93e-6 (favourable), Cervical cancer:6.89e-5 (favourable)",Mixed,Tissue enhanced,,appendix: 36.2;lymph node: 64.3;spleen: 37.7,tonsil: 16.2,Cell line enriched,16.0,MOLT-4: 144.9
150,ZC3H12D,"C6orf95, dJ281H8.1, MCPIP4",ENSG00000178199,Zinc finger CCCH-type containing 12D,6,149446795-149485061,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA036897,Uncertain,,Supported,Nucleoplasm<br>Cytoplasmic bodies,,Mixed,Tissue enhanced,,appendix: 9.6;lymph node: 11.5;tonsil: 11.6,spleen: 5.9,Cell line enhanced,,Daudi: 5.7;HDLM-2: 31.7;REH: 6.4
